アリソールA
Based on 5 publication(s) in Google Scholar
Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.59%
- CAS 番号: 19885-10-0
- 分子式: C30H50O5
- 分子量:490.72
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
AMPK アイソフォーム固有の製品をすべて表示
More
生物活性
|
MMP-9 |
MMP-2 |
PPARα |
IL-6 |
IL-1β |
IL-8 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Erythrocyte | IC50 |
13.8 μM
Compound: 57a
|
Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 72 hrs by [3H]-hypoxanthine incorporation based liquid scintillation counting method
Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 72 hrs by [3H]-hypoxanthine incorporation based liquid scintillation counting method
|
[PMID: 35985254] |
| HepG2 | EC50 |
10.16 μM
Compound: 23
|
Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay
Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay
|
[PMID: 31494470] |
| HepG2 2.2.15 | CC50 |
0.062 mM
Compound: 1
|
Cytotoxicity against human HepG2.2.15 cells
Cytotoxicity against human HepG2.2.15 cells
|
[PMID: 18644720] |
| HepG2 2.2.15 | IC50 |
>2.4 mM
Compound: 1
|
Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV e antigen secretion
Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV e antigen secretion
|
[PMID: 18644720] |
| HepG2 2.2.15 | IC50 |
0.039 mM
Compound: 1
|
Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV surface antigen secretion
Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV surface antigen secretion
|
[PMID: 18644720] |
Alisol A (2.5-40 μM; 24 h) suppresses proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells[3].
Alisol A (1-5 μM) concentration-dependently restores the levels of p-AMPK and p-ACC in HepG2 cells treated with free fatty acids (FFA)[4].
Alisol A (40 μM; 24-72 h) inhibits the proliferation of human aortic endothelial cells (HAECs)[5].
Alisol A (5-160 µM; 24 h) inhibits the proliferation of HCT-116 and HT-29 cells in a dose-dependent manner[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231
-
Concentration:0, 5 μM
-
Incubation Time:24 h
-
Result:Downregulated MMP-2/-9.
Alisol A (150 ppm; p.o.; in diet; 16 weeks) significantly reduces the aortic plaque area in ApoE-/- mice with atherosclerosis, without obvious effect on blood lipid levels[5].
Alisol A (25-100 mg/kg; i.g.; twice daily; 12 weeks) alleviates arterial plaque by activating AMPK/SIRT1 signaling pathway in apoE-deficient mice[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (6 weeks old) with high-fat diet-induced obesity[4]
-
Dosage:100 mg/kg
-
Administration:Intraperitoneal injection, once daily, for 4 weeks
-
Result:Reduced body weight and abdominal fat mass, improved plasma lipid profiles (decreased TC, TG, LDL-C, NEFA, FABP4).
Enhanced glucose tolerance and insulin sensitivity, alleviated hepatic steatosis (reduced fat vacuoles and lipid deposition).
Decreased inflammatory cytokine expression (TNF-α, IL-1β, IL-6, IL-8) in adipose tissue, and activated the AMPK/ACC/SREBP-1c pathway (increased p-AMPK, p-ACC, decreased SREBP-1c) in liver, skeletal muscle, and adipose tissue.
-
Animal Model:Male C57BL/6 background ApoE-/- mice (6-week-old), high-fat diet-induced atherosclerosis model[7]
-
Dosage:25 mg/kg, 100 mg/kg
-
Administration:Intragastric administration, twice daily, 12 weeks
-
Result:Attenuated high-fat diet-induced body weight gain, reduced aortic plaque area, widened the inner diameter of the aortic arch.
Inhibited the expression of ICAM-1, IL-6, and MMP-9 in aortic plaques, and increased the expression of PPARα, PPARδ, p-AMPK, SIRT1, and IkBa in the liver.
化学情報
-
CAS 番号 19885-10-0
-
性状 Solid
-
分子量 490.72
-
分子式 C30H50O5
-
Color White to light yellow
-
SMILES
C[C@]([C@@]1(C2=C([C@H](C)C[C@H](O)[C@@H](O)C(C)(O)C)CC1)C)(CC[C@@]3([H])C4(C)C)[C@]([C@H](C2)O)([H])[C@]3(CCC4=O)C
-
別名
Alisol A; Alisol-A
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Molecules
Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells. [Abstract]2019 Oct 10;24(20):3651. PMID: 31658635 -
Vet Microbiol
Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus. [Abstract]2025 Sep 15:310:110730. PMID: 40976146 -
Nephrology (Carlton)
Alisol A inhibits the circ_0001831/miR-346/LIN28B pathway to ameliorate high glucose-induced injury of human renal mesangial cells. [Abstract]2024 Mar;29(3):154-163. PMID: 38013222 -
Biomed Pharmacother
A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway. [Abstract]2024 Jul:176:116908. PMID: 38850668 -
溶剤 & 溶解度
DMSO : 100 mg/mL (203.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (284 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Matsuda H, et al. Studies on Alismatis Rhizoma. II. Anti-complementary activities of methanol extract and terpene components from Alismatis Rhizoma (dried rhizome of Alisma orientale). Biol Pharm Bull. 1998 Dec;21(12):1317-21. [Content Brief]
[2]. Zhang Q, et al. Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4647-50. [Content Brief]
[3]. Lou C, et al. Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells. Molecules. 2019 Oct 10;24(20):3651. [Content Brief]
[4]. Ho C, et al. Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway. J Cell Mol Med. 2019 Aug;23(8):5108-5118. [Content Brief]
[5]. Ma Y, et al. Alisol A inhibits and stabilizes atherosclerotic plaques by protecting vascular endothelial cells. Front Pharmacol. 2024 Oct 25;15:1493948. [Content Brief]
[6]. Han W, et al. Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling. Oncol Lett. 2022 Jun 7;24(2):249. [Content Brief]
[7]. Wang K, et al. Alisol A Alleviates Arterial Plaque by Activating AMPK/SIRT1 Signaling Pathway in apoE-Deficient Mice. Front Pharmacol. 2020 Nov 2;11:580073. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0378 mL | 10.1891 mL | 20.3782 mL | 50.9455 mL |
| 5 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL | 10.1891 mL | |
| 10 mM | 0.2038 mL | 1.0189 mL | 2.0378 mL | 5.0946 mL | |
| 15 mM | 0.1359 mL | 0.6793 mL | 1.3585 mL | 3.3964 mL | |
| 20 mM | 0.1019 mL | 0.5095 mL | 1.0189 mL | 2.5473 mL | |
| 25 mM | 0.0815 mL | 0.4076 mL | 0.8151 mL | 2.0378 mL | |
| 30 mM | 0.0679 mL | 0.3396 mL | 0.6793 mL | 1.6982 mL | |
| 40 mM | 0.0509 mL | 0.2547 mL | 0.5095 mL | 1.2736 mL | |
| 50 mM | 0.0408 mL | 0.2038 mL | 0.4076 mL | 1.0189 mL | |
| 60 mM | 0.0340 mL | 0.1698 mL | 0.3396 mL | 0.8491 mL | |
| 80 mM | 0.0255 mL | 0.1274 mL | 0.2547 mL | 0.6368 mL | |
| 100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.5095 mL |
Alisol A 関連分類
HY-N0853 関連分類
Powered by Bioz